Accessibility Menu
Kronos Bio logo

Kronos Bio(NASDAQ) KRON

This security has been delisted. This page is retained for historical reference.

Kronos Bio last closing stock price
MetricPriceDate
Last closeUSD 0.882025-06-20
Kronos Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.41%USD 0.892025-06-13
1 month+31.15%USD 0.672025-05-21
3 month+1.08%USD 0.872025-03-21
Year to date-7.37%USD 0.952024-12-31
1 year-15.38%USD 1.042024-06-20
3 year-75.21%USD 3.552022-06-21
Since inception-96.75%USD 27.072020-10-09

KRON News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

KRON Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-943.21%

Net Income Margin

-874.08%

Return on Equity

-69.80%

Return on Capital

-82.58%

Return on Assets

-69.22%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$8.84M

Operating Income

-$70.34M

EBITDA

-$49.14M

Operating Cash Flow

-$54.38M

Capital Expenditure

$3.00K

Free Cash Flow

-$54.38M

Cash & ST Invst.

$99.73M

Total Debt

$24.09M

Kronos Bio Performance Analysis

Kronos Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 6,288,000N/A
20242024-12-31USD 9,848,00056.6%
Kronos Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-306.7%
Q32024-09-30-11.8%
Q42024-12-31-4.2%
Q12025-03-31-17.9%
Kronos Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -2.76N/A
20222022-12-31USD -2.37-14.1%
20232023-12-31USD -1.95-17.7%
20242024-12-31USD -1.43-26.6%
Kronos Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3046.0%
Q32024-09-3014.8%
Q42024-12-31-87.0%
Q12025-03-3167.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2025YOY CHG

Revenue

$1.86M

-26.0%

Gross Profit

$1.52M

-39.8%

Gross Margin

81.33%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

8

N/A

Net Income

-$8.36M

+72.1%

EBITDA

-$6.15M

+67.1%

Quarterly Fundamentals

Name
Q1 2025YOY CHG

Total Cash

$99.73M

-34.4%

Total Debt

$24.09M

-12.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$20.45M

-16.4%

Short Term Debt

$7.28M

+20.6%

Return on Assets

-69.22%

N/A

Return on Invested Capital

-85.15%

N/A

Free Cash Flow

-$12.84M

+46.3%

Operating Cash Flow

-$12.84M

+46.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALVRAlloVir, Inc.
$9.81+4.14%
SGTXSigilon Therapeutics, Inc.
$22.47-2.56%
RNTXRein Therapeutics Inc.
$0.78-1.23%
ACHLAchilles Therapeutics plc
$1.48+0.68%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.